ClinicalTrials.gg
Active, not recruitingNCT06754462Updated Apr 22, 2026

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

A Phase 2 interventional study of IMVT-1402 and Placebo in Rheumatoid Arthritis, sponsored by Immunovant Sciences GmbH. Active, not recruiting at 83 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
383rd of 771
120 · median 120
Started
2025
with 30 others
Phase 2
215 of 975
12 open now
Primary completion
2027-09
later than 59 of 121 live
Registered
932nd of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 383rd largest by planned enrollment of the 771 interventional ones that give a count, is one of 31 that started in 2025, is one of 215 in phase 2, reaches primary completion later than 59 of the 121 other live ones, and was the 932nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).

Read the detailed description

The primary objective is to evaluate the effects of IMVT-1402 compared to placebo, as measured by the American College of Rheumatology 20% (ACR20) response at Week 28.

The total duration of study participation is expected to be up to 86 weeks for an individual participant with 16 weeks of open-label treatment, 12 weeks of blinded randomized treatment, and 48 weeks of optional long-term extension treatment.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Anticitrullinated protein autoantibodies
  • Difficult-to-treat
  • Anti-FcRn
  • IMVT-1402
  • Autoimmune Diseases
  • Imeroprubart
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female participants of age >18 years will be enrolled.
  • Diagnosis of 'definite RA' according to the 2010 ACR/ European Alliance of Associations for Rheumatology (EULAR) Rheumatoid Arthritis Classification Criteria.
  • Greater than or equal to 6/68 in tender joint count (TJC) and ≥ 6/66 swollen joint count (SJC) at both Screening and Baseline visits.
  • C-reactive protein ≥ (ULN) at Screening Visit.
  • Elevated immunoglobulin G (IgG) + ACPA at the Screening Visit.
  • Inadequate response to at least 2 classes of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs).

Additional inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Have received rituximab and experienced insufficient efficacy or loss of efficacy
  • History of any chronic inflammatory arthritis with onset prior to age 18 or history of acute inflammatory joint disease of different origin from RA.
  • Active or history of malignancy within 5 years prior to Screening Visit.
  • Medical history of primary immunodeficiency, T cell or humoral, including common variable immunodeficiency.
  • Used any nonimmunosuppressive fragment crystallizable (Fc)-based therapeutic protein (e.g., monoclonal antibody [mAb] or Fc-fusion protein) within 4 weeks prior to or at Screening Visit.
  • Used any anti-FcRn treatment within 2 months prior to or at Screening Visit or have a documented history of non-response to prior anti-FcRn treatment.

Other, more specific exclusion criteria are defined in the protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    IMVT-1402 Dose 1

    Drug: IMVT-1402

  • Experimental
    IMVT-1402 Dose 2

    Drug: IMVT-1402

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered once weekly by subcutaneous injection.

  • DrugPlacebo

    Administered once weekly by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who maintain ACR20 response at Week 28

    Time frame: Week 28

Secondary outcomes

  1. Change in Clinical Disease Activity Index (CDAI) score from Week 16 to Week 28

    Time frame: Week 16 to Week 28

  2. Change in Simplified Disease Activity Index (SDAI) score from Week 16 to Week 28

    Time frame: Week 16 to Week 28

07

Study locations

83 sites
  • Site Number - 1018
    Mesa, Arizona 85210, United States
  • Site Number - 1019
    Sun City, Arizona 85351, United States
  • Site Number - 1022
    Covina, California 91722, United States
  • Site Number - 1028
    San Leandro, California 94578, United States
  • Site Number - 1024
    Temecula, California 92592, United States
  • Site Number - 1033
    Tujunga, California 91042, United States
  • Site Number - 1023
    Whittier, California 90602, United States
  • Site Number - 1020
    Denver, Colorado 80230, United States
  • Site Number - 1015
    Jupiter, Florida 33458, United States
  • Site Number - 1002
    Miami, Florida 33143, United States
  • Site Number - 1027
    Plantation, Florida 33324, United States
  • Site Number - 1005
    Winter Park, Florida 32789, United States
  • Site Number - 1012
    Zephyrhills, Florida 33542, United States
  • Site Number - 1001
    Gainesville, Georgia 30501, United States
  • Site Number - 1034
    Chicago, Illinois 60607, United States
  • Site Number - 1006
    Cumberland, Maryland 21502, United States
  • Site Number - 1007
    Hagerstown, Maryland 21740, United States
  • Site Number - 1031
    Rockville, Maryland 20850, United States
  • Site Number - 1008
    Worcester, Massachusetts 01605, United States
  • Site Number - 1021
    Saint Clair Shores, Michigan 48081, United States
  • Site Number - 1030
    Kansas City, Missouri 64151, United States
  • Site Number - 1010
    Summit, New Jersey 07901, United States
  • Site Number - 1004
    Charlotte, North Carolina 28207, United States
  • Site Number - 1035
    Statesville, North Carolina 28625, United States
  • Site Number - 1000
    Duncansville, Pennsylvania 16635, United States
  • Site Number - 1016
    Jackson, Tennessee 38305, United States
  • Site Number - 1026
    Memphis, Tennessee 38119, United States
  • Site Number - 1029
    Murfreesboro, Tennessee 37128, United States
  • Site Number - 1037
    Allen, Texas 75013, United States
  • Site Number - 1017
    Colleyville, Texas 76034, United States
  • Site Number - 1036
    Katy, Texas 77494, United States
  • Site Number - 1014
    Mesquite, Texas 75150, United States
  • Site Number - 1013
    Tomball, Texas 77375, United States
  • Site Number - 1025
    Tomball, Texas 77377, United States
  • Site Number - 5003
    Buenos Aires, 1417, Argentina
  • Site Number - 5001
    Buenos Aires, 1425, Argentina
  • Site Number -5004
    Buenos Aires, C1046, Argentina
  • Site Number - 5002
    Buenos Aires, C1118AAF, Argentina
  • Site Number - 5005
    Buenos Aires, C1180AAX, Argentina
  • Site Number - 5000
    San Miguel de Tucumán, 4000, Argentina
  • Site Number - 5603
    Plovdiv, 4000, Bulgaria
  • Site Number - 5605
    Plovdiv, 4002, Bulgaria
  • Site Number - 5602
    Plovdiv, 4004, Bulgaria
  • Site Number - 5604
    Rousse, 7000, Bulgaria
  • Site Number - 5606
    Sevlievo, 5400, Bulgaria
  • Site Number - 5600
    Sofia, 1336, Bulgaria
  • Site Number - 5601
    Sofia, 1680, Bulgaria
  • Site Number - 3204
    Brno, 638 00, Czechia
  • Site Number - 3202
    Ostrava, 702 00, Czechia
  • Site Number - 3203
    Praha 2 Nove Mesto, 128 50, Czechia
  • Site Number - 3201
    Uherské Hradiště, 686 01, Czechia
  • Site Number - 3200
    Zlín, 760 01, Czechia
  • Site Number - 8000
    Tbilisi, 0159, Georgia
  • Site Number - 8001
    Tbilisi, 0160, Georgia
  • Site Number - 8003
    Tbilisi, 0186, Georgia
  • Site Number - 6500
    Hamburg, 20095, Germany
  • Site Number - 6501
    Ratingen, 40878, Germany
  • Site Number - 7554
    Budapest, 1027, Hungary
  • Site Number - 7555
    Budapest, 1027, Hungary
  • Site Number - 7550
    Hódmezővásárhely, 6800, Hungary
  • Site Number - 7553
    Kecskemét, 6000, Hungary
  • Site Number - 7551
    Székesfehérvár, 8000, Hungary
  • Site Number - 7552
    Veszprém, 8200, Hungary
  • Site Number - 3005
    Bialystok, 15-879, Poland
  • Site Number - 3007
    Elblag, 82-300, Poland
  • Site Number - 3009
    Lublin, 20-607, Poland
  • Site Number - 3006
    Nadarzyn, 05-830, Poland
  • Site Number - 3008
    Poznan, 60-848, Poland
  • Site Number - 3000
    Poznan, 61-397, Poland
  • Site Number - 3003
    Sochaczew, 96-500, Poland
  • Site Number - 3004
    Warsaw, 02-665, Poland
  • Site Number - 3002
    Wroclaw, 53-673, Poland
  • Site Number - 7500
    Brasov, 500283, Romania
  • Site Number - 7502
    Bucharest, 020475, Romania
  • Site Number - 7501
    Râmnicu Vâlcea, 240636, Romania
  • Site Number - 7104
    Barcelona, 08208, Spain
  • Site Number - 7101
    Bilbao, 48013, Spain
  • Site Number - 7102
    Málaga, 29009, Spain
  • Site Number - 7100
    Seville, 41009, Spain
  • Site Number - 7000
    Edinburgh, EH4 2XU, United Kingdom
  • Site Number - 7001
    London, SE5 9RJ, United Kingdom
  • Site Number -7002
    North Shields, NE29 8NH, United Kingdom
  • Site Number - 7003
    Wolverhampton, WV10 0QP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 32 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Dec 31, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06754462
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Jan 10, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Apr 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeroprubart

Start the discussion